Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of AIN457 in ankylosing spondylitis
NCT01109940Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2010
- Primary completion
- Dec 2012
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of secukinumab in ankylosing spondylitis (AS), sponsored by Novartis. Started Apr 2010; status: completed.
02
Drugs
secukinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT01109940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01109940.